| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Charles River Laboratories International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$198.55 |
| 52 Week High | US$275.00 |
| 52 Week Low | US$161.65 |
| Beta | 1.38 |
| 11 Month Change | -8.19% |
| 3 Month Change | -11.66% |
| 1 Year Change | -1.69% |
| 33 Year Change | -52.28% |
| 5 Year Change | 53.10% |
| Change since IPO | 802.50% |
Recent News & Updates
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10
Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Recent updates
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Shareholder Returns
| CRL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.7% | 2.2% | 4.5% |
| 1Y | -1.7% | 4.2% | 21.7% |
Return vs Industry: CRL underperformed the US Life Sciences industry which returned 3.3% over the past year.
Return vs Market: CRL underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| CRL volatility | |
|---|---|
| CRL Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CRL has not had significant price volatility in the past 3 months.
Volatility Over Time: CRL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 21,100 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Charles River Laboratories International, Inc. Fundamentals Summary
| CRL fundamental statistics | |
|---|---|
| Market cap | US$10.51b |
| Earnings (TTM) | US$431.79m |
| Revenue (TTM) | US$4.08b |
23.7x
P/E Ratio2.5x
P/S RatioIs CRL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRL income statement (TTM) | |
|---|---|
| Revenue | US$4.08b |
| Cost of Revenue | US$2.61b |
| Gross Profit | US$1.47b |
| Other Expenses | US$1.04b |
| Earnings | US$431.79m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.36 |
| Gross Margin | 35.98% |
| Net Profit Margin | 10.59% |
| Debt/Equity Ratio | 63.2% |
How did CRL perform over the long term?
See historical performance and comparison